

Thes
equiv. NL 8802657



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 315 079
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88118025.1

(51) Int. Cl.4: A61K 9/10 , A61K 9/50

(22) Date of filing: 28.10.88

(30) Priority: 28.10.87 JP 272770/87

(43) Date of publication of application:
10.05.89 Bulletin 89/19

(54) Designated Contracting States:
AT DE SE

(71) Applicant: NIPPON SHINYAKU COMPANY,
LIMITED
14, Kissyoin Nishinoshio Monguchicho
Minami-ku Kyoto-shi Kyoto 601(JP)

(72) Inventor: Sugiyama, Makoto
623 Otowa Otsudecho
Yamashina-ku Kyoto 607(JP)
Inventor: Okita, Atsuhiko
16-16 Koyocho
Otsu 520-02(JP)
Inventor: Seki, Junzo
1-5-A-317 Hozumi
Ibaragi 567(JP)

(74) Representative: Wey, Hans-Heinrich, Dipl.-Ing.
Patentanwälte Wey & Partner
Widenmayerstrasse 49
D-8000 München 22(DE)

(57) Drug carriers.

(57) A drug carrier in the form of a fat emulsion, which contains a drug and has a mean particle diameter of less than 200 nm.

EP 0 315 079 A1

Xerox Copy Centre

DRUG CARRIERS

The present invention relates to an improved drug carrier in order to improve delivery of a drug contained therein from the blood stream or an applied site into lesional tissue.

Various investigations have been hitherto made on drug carriers for improving delivery of a drug contained from the blood stream or an applied site to a lesional tissue. For example, there is a method for utilizing liposome prepared by phospholipid having incorporated therein ("Drug Carriers in Biology and Medicine" (1979), Ed. by G. Gregoriadis, Academic Press).

According to this method, however, the method encounter defects that (1) there are many problems in stability of liposome enveloping an aqueous phase with a lipid bilayer during its storage, (2) in the case of administration into blood, almost all liposomes are taken up into a tissue with a developed reticuloendothelial system (RES) such as liver, spleen, etc. so that they are difficult to be distributed to other cells or tissues, etc. These are believed to be because liposome has a structure wherein the inner and outer aqueous phases are separated from each other by a phospholipid bilayer and liposome is thus unstable to various forces. An increase in particle diameter due to aggregation was also known as a defect during its storage.

According to investigations in recent years, there is known a technique in which various drugs are dissolved in a fat emulsion having a particle diameter of 0.2 μm composed of soybean oil and yolk lecithin heretofore used clinically as fluid supplementation for purposes of supplementing nutrients and the solution is used; good results obtained thereby for the object described above (SAISHIN IGAKU (Latest Medicine), 40, 1806-1813 1980)). This carrier is characterized in that it has no aqueous phase inside and can be extremely stably stored as compared to liposomes.

However, the carrier has a property that is readily taken up into the aforesaid reticulo-endothelial system such as liver, etc. Such a rapid metabolism was desired as a high calorie fluid supplementation but involved problems of causing poor distribution of a drug into other tissues as a drug carrier suited for the object described above, etc. and was not necessarily desirable.

Further, an art of using fat emulsion wherein 90% of it is 100 ± 30 nm as a carrier for pharmaceuticals is disclosed in Japanese Laid Open 63/500456. However this art is also characterized in accumulation on reticulo-endothelial system such as liver and spleen and, as already described, there is a problem in the delivery of drug to other tissues.

As a means for solving the foregoing problems, a technique of applying serum lipoproteins composed of a simple lipid (including sterols, same as in the present specification), a complex lipid and an apolipoprotein as a drug carrier was known (Japanese Patent Application Laid-Open No. 60-163824). However, this carrier is to introduce a drug into cells by physiological and specific recognition of the lipoprotein. Therefore the carrier is rapidly transferred into tissue via its receptor so that disappearance from the blood is relatively rapid. For this reason, transfer into a tissue having a poor receptor activity is not always sufficient. Furthermore, apolipoprotein is indispensable as its constituent so that the technique involves a defect in industrial technique that results in high production costs.

Further, an attempt of making fat emulsion of 200 nm particle size more fine is known (cf. Japanese Laid Open 62/29511). However, in this art, yolk lecithin used is a little and, accordingly, the resulting microparticles are re-coagulated with an elapse of time whereby there is a problem instability. Moreover, there is a disadvantage as to the stability in vivo, so said art is not desirable in terms of delivery to other tissues.

In general, a drug administered moves and distributed in the body due to properties inherently possessed by its drug molecule. Then, the drug reaches the site of action to exhibit its pharmacological effects. In this case, it is desired that the drug is concentrated only on the site necessary for exhibiting the pharmacological effects but the drug is generally distributed over the entire body and the drug moves also to a site that does not require the drug. This sometimes becomes a cause for side effects. Thus, it becomes important and necessary to improve disposition of a drug in the body.

In view of the circumstances described above, the present inventors have continued to investigate novel drug carriers, (1) without affecting pharmacological activities per se of a drug, (2) capable of effective delivery of a drug into focal tissue, (3) capable of reducing uptake by the reticulo-endothelial system, (4) capable of durating a concentration of a drug in blood and (5) capable of reducing a dose of drug required. As a result, they have finally succeeded in accomplishing the present invention.

The feature of the present invention lies in the following points.

- (1) The drug carrier is a fat emulsion constituted by two of a lipophilic substance as the core and a lipophilic substance having covered the surface thereof and is not in such a form as in liposome wherein the aqueous phase is present inside;
- (2) In the drug carrier, a drug is present in a state of dispersion, dissolution, formation of mixed micelles or chemical binding with lipid; and,
- (3) A particle diameter is in a range of not less than 5 nm to less than 200 nm.

Hereafter, these points will be described in detail.

The drug carrier of the present invention has a form as a stable fat emulsion. It is desired that its particle diameter be in a range of not less than 5 nm to less than 200 nm, in order to avoid uptake into the reticulo-endothelial system. By super finely dividing the drug carrier, its blood concentration can be maintained in a higher level than in a fat emulsion having a diameter of about 0.2 μm . Particularly preferred is a diameter of 100 nm or less. This is because the drug carrier can easily exudate out of blood vessel through a region in which vasopermeability is accentuated.

It is known that various regions called pore systems (it is said that a small pore system having a diameter up to 9 nm and a large pore system having a diameter of 25 to 70 nm are present and it is known that the vaso-permeability is further increased in various focal regions including neoplastic vessels) or other slits between cells are present in blood vessels and vasopermeability is accentuated in various focal regions including inflammation, tumor and atherosclerosis. In such a region, the drug carrier of the present invention is selectively exudated out of blood vessel in large amounts and transferred into focal tissue. At the same time, the drug contained in the drug carrier is also delivered into the lesion. By this, the drug can easily be delivered to the focal region selectively so that a drug concentration at the focal region increases and its effect can be enhanced. Further by applying the drug carrier of the present invention, a drug can be administered simultaneously with lipid so that sustained releasability of a drug and lymphotropic properties of a drug can be improved. The drug carrier of the present invention also subjects to phagocytizable properties to phagocyte.

The characteristic feature of the present invention lies in using super finely divided lipid as a drug carrier. By the super finely divided particles, the problems described above that not only the foregoing effects are exhibited but also uptake by the reticulo-endothelial system is prohibited, etc. can be solved at once. By this, an effect of keeping a drug concentration in blood can also be obtained.

The drug carrier in accordance with the present invention is characterized in that by using larger amounts of the surface layer (for example, compound lipid) in its proportion to the core (for example, simple lipid), as compared to the conventional high calorie fluid supplementation, comprising soybean oil and yolk lecithin, super finely divided particles are realized.

In order to facilitate super finely divided particles in the drug carrier of the present invention, it is desired that the content of the surface layer (for example, complex lipid) be in a range of 15% to 70%. This is because a surface area of the core in the drug carrier is increased by super finely division so that it is necessary to increase an amount of the complex lipid in order to cover the core as a surface layer and stabilize the emulsion. In the case of using less than 15% of complex lipid, it is unavoidable to intermingle particles having a diameter of 0.2 μm or more; in the case of using more than 70% of complex lipid, it is unavoidable to intermingle liposome particles. By this compositional constitution, a stable emulsion of super finely divided lipid emulsion can be obtained and is usable as an extremely excellent drug carrier, which has been made clear by the present invention for the first time.

That is, it is considered that the drug carrier of the present invention would be in the form of a fat emulsion composed of a substance as the core and a substance as the surface layer, wherein (1) the substance constituting the core of the fat emulsion is a simple lipid, a derived lipid, a drug itself or a mixture thereof and a ratio of said substance in the drug carrier is 30 to 85%; (2) the substance constituting the surface layer of the fat emulsion is a complex lipid, a derived lipid, a drug itself or a mixture thereof and a ratio of said substance in the drug carrier is 15 to 70%; and by possessing properties (1) and (2) at the same time, the drug carrier containing a drug therein having a mean particle diameter of less than 200 nm can be obtained.

In the present invention, it is required that the mode of containing the drug should be dispersing or dissolving in the drug carrier, forming a mixed micelle with a constituent(s) of the drug carrier or chemically binding with a constituent(s) of the drug carrier so that the applied drug is not readily released from the drug carrier.

As the lipid used in the drug carrier of the present invention, mention may be made of a simple lipid, derived lipid or a complex lipid derived from natural animal, vegetable or mineral or a mixture thereof. Examples include a simple lipid, derived lipid or a complex lipid derived from yolk, soybean, cotton,

linseed, corn, sesame, peanut, safflower, bovine tissue, hog tissue, sheep tissue, etc. or a simple lipid, derived lipid or a complex lipid purely synthetically prepared.

Examples of the simple lipid include neutral lipids such as refined soybean oil, cotton seed oil, linseed oil, sesame oil, corn oil, peanut oil, safflower oil, triolein, trilinolein, tripalmitin, tristearin, tri-myristin, triarachidonin etc. The simple lipid also embraces cholesterol derivatives such as cholesteryl oleate, cholesteryl linoleate, cholesteryl myristate, cholesteryl palmitate, cholesteryl arachidonate, etc. This is because neutral lipids are relatively easily decomposed by various lipases present in blood vessel endothelium, etc., whereas cholesterol derivatives are decomposed only with difficulty by these enzymes and

As the derived lipid, mention may be, for example, cholesterol, fatty acids such as stearic palmitic acid, oleic acid, linoleic acid, linolenic acid, elcosapentaenoic acid, etc. and derivatives thereof, squalene, etc. They may also be used as emulsification aids. Furthermore, oily compounds such as azone, etc. may be exemplified.

As the complex lipid, mention may be made of, for example, phospholipids derived from yolk, soybean, bovine tissue, hog tissue, etc. or phospholipids and glycolipids purely synthetically produced. Examples of phospholipids include phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, etc., which are exemplified by yolk phosphatidyl choline, soybean phosphatidyl choline, dipalmitoyl phosphatidyl choline, di-myristoyl phosphatidyl choline, distearoyl phosphatidyl choline, dioleoyl phosphatidyl choline, dipalmitoyl phosphatidyl inositol, etc. Products obtained by hydrogenation of these phospholipids may also be used. Among them, a representative preferred example is yolk phosphatidyl choline. As the glycolipid, mention may be made of cerebroside, etc. Steryl glucosides, e.g., β -sitosteryl- β -D-glucoside, etc. can also be exemplified. Furthermore, lipids having a charge such as stearyl amine, dicetyl phosphate, phosphatidic acid, etc. may also be used to impart a surface charge to the drug carrier.

The drug to which the present invention is applicable may be any drug so long as it is pharmaceutically acceptable but is not particularly limited. Even a drug that is insoluble or sparingly soluble can also be used. In the present invention, the drug readily forms a complex with the carrier.

In a water-soluble drug, the drug carrier of the present invention can be formed by using the drug chemically bound to the constituents (for example, lipid, etc.) of the carrier.

Even though a drug is unstable in the body and is thus incapable of administration so far, such a drug can also be readily administered by using the drug carrier of the present invention. The drug contained in the drug carrier of the present invention is present in oil droplets of lipids in such a state that is shielded from the surrounding environment so that enzymatic or non-enzymatic decomposition can be prevented.

The drug to which the drug carrier of the present invention is applicable is not particularly limited, as described above. Examples include an anti-inflammatory agent, an analgesic, an anti-allergic agent, an antibiotic, a chemotherapeutic agent, an anti-cancer agent, antiviral agent, anti-atherosclerosis, an anti-lipemic agent, an antiulcer agent, an Immunoregulator, a vaccine, a radical scavenger, a bronchodilator, a hypnotic, a tranquilizer, a topical anesthesia, a diagnostic, etc. Specific examples of these drugs are anticancer agents such as Ancitabine, fluorouracil, mitomycin C, mitomycin C farnesylamide, mitomycin C farnesylacetic amide, Carmofur, Futraful palmitate, 5-fluorouracil myristate, Adriamycin, Daunomycin, Actarubicin, Mazarubicin, Vinblastine, Vincristine, Cytarabine fatty acid esters, Mitotane, Estramustine, etc.; antiviral agents such as Dichloroflavan, etc.; steroid agents (for example, Dexamethasone palmitate, hydrocortisone palmitate, Prednisolone palmitate, Dexamethasone stearate, Methylprednisolone, Paramethasone, Fluocinolone acetonide, Vectamethasone propionate, Hydrocortisone fatty acid esters, Aldosterone, Spironolactone, etc.) and non-steroidal agents (for example, Ibuprofen, Flufenamic acid, Ketoprofen, Phenacetin, Antipyrine, Aminopyrine, Phenylbutazone indoleacetate, Biphenylpropionic acid derivatives, Indometacin, Indometacin ethoxycarbonylmethyl ester, Indometacin stearyl ester, Sodium aurothiomalate cetyl ester, Diclofenac, acetylsalicylic acid and derivatives thereof, etc.). Antiallergic agents such as Trantast, Ketotifen, Azelastine, etc. may also be used. As antibiotics and chemotherapeutic agents, mention may be made of, for example, tetracyclines, Erythromycin, Midecamycin, Amphotericin, Nalidixic acid, Griseofulvin, Minocyclin, etc. As examples of prostaglandines, there may be used PGE1, PGA1, PGA1 alkyl esters, PGE1 alkyl esters, PGE1 derivatives, PGI2 derivatives, PGD2 derivatives, etc. Antihistaminic agents such as Diphenhydramine, Orphenadrine, Chlorphenoxamine, Chlorpheniramine, Promethazine, Meclidine, Cyproheptadine, Loxatidine acetate, etc. are mentioned. Furthermore, as topical anesthesia, mention may be made of Lidocaine, Benzocaine, Dantrolene, Cocaine, Tetracaine, Piperacaine, Mepivacaine, and derivatives thereof, etc. There are also mentioned hepatic disorder improving agents (for example, Marotirate, Glycyrrhetic acid, ethyl acetylglycyrrhinate, methyl glycyrrhinate, etc.), antiulcer agents (for example, Farnesol, Geranlol, Gefarnate, Tepranone, Plaunotol, Sofarcon, etc.). There are also agents acting on central nerves (for example, Phenobarbital, Methaqualon, Heroin, Diazepam, Medazepam,

- Frazepam, Clotiazepam, Etizolam, Mecridine, Bucridine, Adiphenine, Methamphetamine, Imipramine, Chlorimipramine, Amitriptyline, Mianserin, Trimethadione, Phensuximide, Tetrabenazine, Benzquinamide, Camphor, Dimorphoramine, Strychnine, Chlorpromazine, Promethazine, Prochlorperazine, Mequitalazine, Trifluopromazine, Levomepromazine, Difenidol, etc. and derivatives thereof). Also cerebrovasodilators (for example, Cinnarizine, etc.) may be mentioned. As bronchodilators, mention may be made of Vestphyllin and other theophylline derivatives, methylephedrine, etc. Anticholinergic agents (for example, Benztropine, Physostigmine, Atropine, Scopolamine, etc.), parasympathetic blockers (for example, Oxyphencyclidine, Pirenzepine, Etomidine, etc.), calcium blockers (for example, Diltiazem, Nifedipine, Verapamil, etc.), α-blockers (for example, Dibenzamine, Phenoxybenzamine, etc.), antitussive agents (for example, Noscapine, 10 Dextromethorphan, Pentoxyverine, Benproperine, etc.), agents for treating prostatic hypertrophy (for example, Gastrol, Oxendolone, etc.), agents for treating glaucoma (for example, Pilocarpine, etc.), agents acting on smooth muscle (for example, Sparteine, Papaverine, etc.), agents for treating hyperlipidemia (for example, Chlorfibrate, Cimfibrate, Probucol, etc.) and the like. In addition, mention may be made of, for example, amino acids, vitamins, Dilazep, Ubidecarenone, Flavoxate, Cyclosporin, vaccines for influenza, etc., Dibenzothiophene, Diphenylpyraline, Phenovalinium, Metadione, Tofisopam, Limonen, etc.).
- Antioxldants (for example, tocopherol, flavone derivatives, gallic acid derivatives, coffee acid derivatives, Goshipol, Sesamol, oxyfatty acid, camphene, Cineol, Rosmanol, Eugenols, Filozurucine, etc. catechins, lignan homologues, p-coumaric acid, sterols, terpenes, bromophenol, etc.) can also form the drug carrier of the present invention as one of the constituents.
- Further, guiazulene, essential oil type crude drugs (for example, apricot kernel oil, fennel oil, thyme oil, terepenine oil, eucalyptus oil, palm oil, poppy seed oil, tsukaki oil, peppermint oil, clove oil, mint oil, sage oil and other components for spicy crude drugs, etc.) and the like can also form the drug carrier of the present invention as one of the constituent factor of the drug carrier of the present invention.
- As diagnostics, mention may be made of, for example, a compound labeled with a radiisotope, a radioactive drug or iodated poppy oil fatty acid esters as X ray contrast materials, etc.
- The drug to which the drug carrier of the present invention is applicable is not particularly limited as described above but when viewed from characteristics possessed inherently as the drug carrier, drugs which take part in Inflammation, tumor, blood vessel or immune or lymphoid system are generally desired.
- The drug concentration in the drug carrier of the present invention can be suitably varied within a range 30 that the content does not exceed 85% in the drug carrier, according to biological activity of the drug. Further the concentration of the drug carrier of the present invention in medical preparations obtained using the drug carrier of the present invention can be suitably varied and is optional, if desired.
- Upon preparation of the drug carrier of the present invention and medical preparations using the same, various methods for preparing emulsion hitherto performed can apply. For example, they can be prepared 35 according to a method which comprises sufficiently finely dividing all constituents including a drug by means of a homogenizer of Manton-Gaurin type, a microfluidizer, a ultrasonic wave homogenizer, etc. They can be also prepared according to a method which comprises solubilizing the constituents using a surface active agent (for example, bile acid), a water-soluble solvent (for example, ethanol, polyethylene glycol), etc. and then removing the surface activity agent or water-soluble solvent, etc. by dialysis or gel filtration, and 40 the like. Fatty acids or derivatives thereof, etc. may also be added as emulsification aids. Furthermore, the drug carrier and its medical preparations may also be obtained by adding a drug to a fat emulsion free from particles having a diameter of 200 nm or more previously prepared by the aforesaid methods.
- The shape and particle diameter of the drug carrier of the present invention can easily be confirmed by an electron microscope, a particle diameter analyzer of light scattering type, filtration through a membrane 45 filter, etc. As optional components for medical preparations using the drug carrier of the present invention, mention may be made of additives and auxiliary substances used for ordinary injections, etc. Examples are an antioxidant, a preservative, a stabilizer, an isotonic agent, a buffer, etc. Required and optimum amounts of these additives, auxiliary substance or the like can be varied depending upon their purposes.
- The drug carrier of the present invention obtained as described above can be sterilized (for example, 50 sterilized by filtration or with steam under high pressure in an autoclave), if necessary, and sealed in an ampoule together with nitrogen gas. Also if necessary, the drug carrier may be freeze dried. The freeze dried drug carrier of the present invention can be restored by adding an appropriate solution thereto.
- The drug carrier of the present invention is generally administered intravenously to humans and animals but if necessary, can also be administered Intraarterially, Intramuscularly, subcutaneously and the like.
- Furthermore, the drug carrier of the present invention can also be used as an eye drop, a nose drop, an oral agent, a suppository and the like. In this case, additives such as pharmaceutically acceptable bases, excipients and the like can be exemplified as optional components.

(Effects)

According to the present invention, a value for drug availability can be markedly enhanced. The effects of the drug carrier of the present invention can be summarized in that the prior art problems are overcome, 5 (1) delivery of a drug into the focal lesion is improved, (2) uptake by the reticulo-endothelial system is prevented, (3) a blood concentration of drug contained therein can be maintained, (4) stability during storage is ensured, (5) production costs are reduced, etc. These effects have been achieved by the present invention for the first time.

It is also a characteristic that the major constituents of the drug carrier of the present invention are 10 therapeutically acceptable lipids conventionally used for therapy in the clinical field so that they can be used extremely safely.

(Examples)

15 Hereafter the present invention will be explained in more detail, by referring to examples relating to preparation of the drug carrier of the present invention but apparently, is not deemed to be limited thereto.

20 Example 1

To 27 mg of triolein were added 38 mg of yolk lecithin and 10 mg of guaiaculene (antiinflammatory agent) and, 10 ml of physiological saline was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 25 minutes under ice cooling. The formed drug carrier containing guaiaculene was blue and clear. A mean particle diameter of the drug carrier was 26.4 nm when measured by a light scattering particle diameter measurement device. Further in observation by an electron microscope, the drug carrier was recognized to be uniform, spherical ultra finely divided particles. Any lipid bilayer membrane as in liposome was not noted. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and 30 did not contain particles of 0.2 μm or more.

Example 2

35 Yolk lecithin, 2.5 mg and 10 mg of guaiaculene were added and, 10 ml of physiological saline was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier containing guaiaculene had a mean particle diameter of 48.4 nm, according to an apparatus for measuring optical scattering particles. It was also noted that the drug carrier passed by 100% through a 40 filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

Example 3

45 To 100 mg of triolein were added 100 mg of yolk lecithin and 4 mg of a compound (Dexamethasone palmitate) obtained by chemically binding a fatty acid with Dexamethasone (antiinflammatory agent) and, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier containing Dexamethasone palmitate was slightly bluish 50 white and clear. A mean particle diameter of the drug carrier was 29.9 nm when measured by a light scattering particle diameter measurement device.

It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

55

Example 4

To 80 mg of triolein were added 20 mg of cholesteryl linoleate, 100 mg of yolk lecithin and 4 mg of

Dexamethasone palmitate. Then, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier containing Dexamethasone palmitate was slightly bluish white and clear. A mean particle diameter of the drug carrier was 30.6 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

10 Example 5

To 100 mg of cholestrylinolate were added 100 mg of yolk lecithin and 4 mg of Dexamethasone palmitate. Then, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier containing Dexamethasone palmitate was slightly bluish white and clear. A mean particle diameter of the drug carrier was 22.7 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

20 Example 6

To 100 mg of triolein were added 100 mg of yolk lecithin and 10 mg of Diphenhydramine (antihistaminic agent). Then, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier containing Diphenhydramine was slightly bluish white and clear. A mean particle diameter of the drug carrier was 31.6 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

Example 7

35 To 100 mg of triolein was added 100 mg of yolk lecithin. Then, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier was slightly bluish white and clear. A mean particle diameter of the drug carrier was 47.2 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

A compound (Vinblastine palmitate), 500 μg , obtained by chemically binding a fatty acid with Vinblastine (anticancer agent) was added to the drug carrier obtained above. The mixture was gently mixed and stirred for 6 hours to take the drug up into the drug carrier. Thus, the drug carrier containing the drug was obtained.

A compound (5-Fluorouracil palmitate), 500 μg , obtained by chemically binding a fatty acid with 5-Fluorouracil (anticancer agent) was added to the drug carrier obtained above. The mixture was gently mixed and stirred for 6 hours to take the drug up into the drug carrier. Thus, the drug carrier containing the drug was obtained.

50 A compound (Cytarabine levulinate), 500 μg , obtained by chemically binding a fatty acid with Cytarabine (anticancer agent) was added to the drug carrier obtained above. The mixture was gently mixed and stirred for 8 hours to take the drug up into the drug carrier. Thus, the drug carrier containing the drug was obtained.

55 Example 8

To 80 mg of triolein were added 20 mg of cholestrylinolate and 100 mg of yolk lecithin. Then, 10 ml

of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier was slightly bluish white and clear. A mean particle diameter of the drug carrier was 19.1 nm when measured by a light scattering particle diameter measurement device. The analytical results are shown in Fig. 1. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

Example 9

To 20 mg of refined soybean oil was added 20 mg of yolk lecithin. Then, 10 ml of 0.24 M glycerin aqueous solution was added to the mixture. Using a probe type ultrasonic wave homogenizer (Branson Sonifier Model 185), the mixture was subjected to a ultrasonic wave treatment for 60 minutes under ice cooling. The formed drug carrier was slightly bluish white and clear. A mean particle diameter of the drug carrier was 16.1 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

Furthermore, a drug carrier was prepared in a manner similar to above, except for using 40 mg of refined soybean oil. The formed drug carrier was slightly bluish white and clear. A mean particle diameter of the drug carrier was 37.7 nm when measured by a light scattering particle diameter measurement device. It was also noted that the drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

Example 10

To 10 g of soybean oil was added 10 g of yolk lecithin. Then, 1 liter of 0.24 M glycerine aqueous solution was added to the mixture. Using a microfluidizer, the mixture was emulsified. It was noted that the formed drug carrier passed by 100% through a filtering membrane of 0.2 μm and did not contain particles of 0.2 μm or more.

[Test on stability of the drug carrier of the present invention]

Test Example 1-1

The sample obtained in Example 1 was sealed in a brown ampoule of 1 ml volume together with nitrogen gas. A forced deterioration test was performed at 60 °C for 4 weeks in a conventional manner. The residual rate of guiazulene was 98.3% more and it was confirmed that the drug carrier of the present invention had effects in stability of the drug.

Test Example 1-2

The samples obtained in Examples 1, 3 and 4 described above were sealed, respectively in a brown ampoule of 1 ml volume together with nitrogen gas. After a sterilizing treatment of the ampoules with steam under high pressure in an autoclave, a particle diameter of each sample was measured by a light scattering particle diameter measurement device. There was no significant difference between prior to and after the treatment. Neither aggregation nor increase in the particle diameter was noted. Further they were stored at 4 °C for 6 months but no change such as aggregation, etc. was noted.

Test Example 1-3

The sample obtained in Example 3 described above was freeze dried in a conventional manner. Thereafter, distilled water for injection was added to the sample followed by stirring to restore. Then a particle diameter of the sample was measured by a light scattering particle diameter measurement device.

A mean particle diameter was 28.3 nm. There was neither significant aggregation nor increase in the particle diameter was noted but the sample was uniformly dispersed.

5 [Test on utility of the present invention]

Test Example 2-1

10 The drug carrier of the present invention containing ^3H -labeled Dexamethasone palmitate prepared in a manner similar to Example 3 was used as a test sample. As a comparative sample, a fat emulsion having a diameter of 0.2 μm as the prior art was used. This comparative sample was obtained by adding 10 ml of 0.24 M glycerin aqueous solution to 4 mg of ^3H -labeled Dexamethasone palmitate, 100 mg of refined soybean oil and 12 mg of yolk lecithin.

15 The test sample and the comparative sample were intravenously administered to rats. Then, a change in blood concentration was examined.

Change in the total radioactivity in plasma when the test sample and the comparative sample were intravenously administered to the tail vein of SD strain male rats (weighing about 210 g) in a dose of 0.05 mg/kg calculated as Dexamethasone is shown in Fig. 2, by calculating into Dexamethasone. The comparative sample rapidly disappeared from plasma but disappearance of the test sample was gentle. Half life periods in the distribution phases were 10.5 minutes and 5.5 minutes, respectively.

Test Example 2-2

25 Delivery of the drug into an inflammatory region induced by carrageenin edema was compared between the test sample and the comparative sample, using the drug carrier of the present invention ^3H -labeled Dexamethasone palmitate prepared in a manner similar to Example 4 as a test sample and the same comparative sample as used in Test Example 2-1.

30 **Table 1 Delivery of Drug into Carrageenin Inflammatory Region**

		<u>Test Sample</u>	<u>Comparative Sample</u>
35	Paw with inflammation (ng)	475 \pm 175	154 \pm 17
	(ng/g)	204 \pm 53	64 \pm 8
	Control paw (ng)	164 \pm 19	89 \pm 24
40		(ng/g)	94 \pm 8
	Edema region	538 \pm 142	94 \pm 42
	Plasma	448 \pm 38	122 \pm 12
45		Indication is (mean \pm standard deviation)	

Carrageenin edema was induced by subcutaneously administering 0.1 ml of 0.5% λ -carrageenin to SD strain male rats weighing about 195 g) at one paw heel. Two hours after the administration of carrageenin, the test sample and the comparative sample were intravenously administered in the tail vein in a dose of 0.5 mg/kg calculated as Dexamethasone. Sixty minutes after the intravenous administration, blood was collected from the aorta in the abdomen to obtain plasma. At the same time, the paw with inflammation and the opposite paw control paw) were cut off from the ankle joint. Each radioactivity was measured after treating with a sample oxidizer.

55 In Table 1, with respect to the test sample, large amounts of the drug were transferred into the inflammatory region (edema region) and strong accumulation onto the inflammatory region was noted, as compared to the comparative sample. A drug concentration of 5.7 times that of the comparative sample was noted in the edema region induced by inflammation.

Test Example 2-3

Table 2 indicates the results of comparison in delivery of a drug into the hydrothorax and the major organs in rats with pleurisy model, using the same test sample and comparative sample as used in Test Example 2-2 described above.

2% λ -Carrageenin, 0.1 ml, was administered to SD strain male rats (weighing about 300 g) at the thoracic cavity. Two and half hours after the administration of carrageenin, the test sample and the comparative sample were intravenously administered in the tail vein in a dose of 1.25 mg/kg when calculated as Dexamethasone. Thirty minutes after the intravenous administration, blood was collected from the aorta in the abdomen and fluid in the thoracic cavity was washed out with physiological saline to make 10 ml. Its radioactivity was determined. At the same time, the major organs were ecorized. Each radioactivity was measured after treating with a sample oxidizer.

Table 2 Transfer into Inflammatory Region and Major Tissues

		<u>Test Sample</u>	<u>Comparative Sample</u>
20	Fluid in the thoracic cavity	(μ g) 2.65	0.68
25	Diaphragm	(μ g/g) 1.06	0.68
30	Spleen	(μ g/g) 3.05	27.34
35	Liver	(μ g/g) 7.71	17.84
40	Heart	(μ g/g) 1.53	1.53
45	Lung	(μ g/g) 2.36	1.93
50	Kidney	(μ g/g) 2.66	1.37
55	Plasma	(μ g/ml) 10.07	2.37

Indication is a mean value when converted into Dexamethasone.

In Table 2, with respect to the test sample, large amounts of the drug were delivered into the inflammatory region (hydrothoracic region) and strong accumulation onto the inflammatory region was noted, as compared to the comparative sample. A drug concentration of 3.9 times that of the comparative sample was noted in the fluid in the thoracic cavity. In distribution into the major organs, the test sample showed extremely low transfer in transfer into organs having developed reticulo-endothelial system such as liver and spleen.

Test Example 2-4

The same test sample and comparative sample as used in Test Example 2-2 described above were intravenously administered to BALB/C male mice (weighing about 25 g). Thirty minutes after the administration, a concentration of the unchanged drug and a concentration of Dexamethasone as its metabolite were determined in plasma and liver. The dose was made 5 mg/kg when calculated as Dexamethasone.

Table 3 shows each concentration of the unchanged drug (Dexamethasone palmitate, its concentration was converted into Dexamethasone) and its metabolite (Dexamethasone) separately determined quantitatively.

In the case of the test sample, a concentration in plasma was high and distribution in the liver was low.

Further the test sample was mostly present in plasma as the unchanged drug. In the case of using the drug carrier of the present invention, maintenance of blood concentration of the drug and a preventing effect in uptake into the reticulo-endothelial system are obviously noted.

5	Table 3		
	<u>Test Sample</u>	<u>Comparative Sample</u>	
	<u>(μg/ml, g)</u>	<u>(μg/ml, g)</u>	
10	Unchanged drug in plasma	36.3 ± 2.2	7.7 ± 1.6
	Dexamethasone in plasma	4.6 ± 0.5	5.2 ± 0.9
	Unchanged drug in Liver	not detectable	not detectable
15	Dexamethasone in Liver	24.0 ± 1.2	41.0 ± 1.3
	Liver/Plasma ratio in concentration (total amount)	0.6 ± 0.0	3.0 ± 0.5
20	Indication is (mean \pm standard deviation)		

25 Test Example 2-5

With respect to the same test sample and comparative sample as used in Test Example 2-2 and a physiological saline solution of Dexamethasone phosphate, their pharmacological effects were examined using carrageenin edema inhibition as the index.

30 λ -carrageenin (0.5%, 1 ml) was subcutaneously administered to SD strain male rats (weighing about 160 g) at one paw heel. Thirty minutes after, the test sample, the comparative sample and Dexamethasone phosphate were intravenously administered in the tail vein. For the control group, physiological saline was administered. A volume of the paw was measured prior to the administration of carrageenin and 5 hours after the administration in a conventional manner to determine an edema inhibition ratio.

35 Fig. 3 shows its dose-response curve (indicated as Dexamethasone calculated). Fig. 4 shows a 50% edema inhibition dose (ED₅₀).

It is apparent that the test sample had an antiinflammatory activity by about twice that of the other two samples, even in inflammation of this kind which was not improved with the comparative sample as the prior art. That is, the effect of the drug carrier of the present invention was confirmed as an effect of enhancing the drug effect. It is thus clear that this is because the drug is efficiently delivered to the focal lesion by using the drug carrier of the present invention.

Table 4 50% Edema Inhibition Dose

45	<u>ED₅₀ (mg/kg)</u>	
	Test Sample	0.012
50	Comparative Sample	0.031
	Dexamethasone phosphate	0.023
(Indication is made by conversion into Dexamethasone)		

55 Test Example 2-6

With respect to the same test sample and comparative sample as used in Test Example 2-2 and a physiological saline solution of Dexamethasone phosphate, their pharmacological effects were examined by the inhibition of carrageenin granuloma as the index. Further, weights of thymus and adrenals were examined.

- 5 λ -Carrageenin (2.0%, 4.0 ml) was subcutaneously administered to SD strain male rats (weighing about 160 g) at the back. From on Day 5, each sample was Intravenously administered to the tail vein once daily for 3 days 3 times in total. A dose of the drug administered was made 0.05 mg/kg/once. For the control group, physiological saline was administered. Eight days after, granuloma, thymus and adrenal were ectomized and their weights were measured.
- 10 It is noted from Fig. 5 that the test sample showed obviously strong granuloma formation inhibition activity as compared to the comparative sample and Dexamethasone phosphate and also showed less atrophy in the thymus and the adrenals. That is, it is shown that the test sample had a strong pharmacological effect but less side effects.

15 **Table 5 Weights of granuloma, thymus and adrenal**

	<u>granuloma</u>	<u>Thymus</u>	<u>Adrenal</u>
Control	20.5 \pm 5.4 g	416.0 \pm 63.3 mg	55.2 \pm 9.6 mg
Test Sample	10.9 \pm 1.4 g	205.0 \pm 57.2 mg	44.5 \pm 7.2 mg
Comparative Sample	15.5 \pm 2.6 g	149.8 \pm 31.3 mg	39.6 \pm 2.7 mg

25 Indication is (mean \pm standard deviation)30 **Test Example 2-7**

In order to confirm deliverability to the tumor region, a test was performed.

35 P388 leukemia cells, 10^6 cells, were subcutaneously transplanted to CDFI male mice (weighing about 25 g) at the right front limb. Six days after, the right front limb was cut out and provided for the experiment 5 days after. By this treatment, metastatic cancer model into the right upper arm and the right axilla lymph nodes was obtained. As the test sample, the drug carrier of the present invention prepared in Example 8 using 3 H-labeled cholesteryl linoleate was used. As the comparative sample, a fat emulsion having a diameter of 0.2 μ m, composed of refined soybean oil and yolk lecithin hitherto known in which 3 H-labeled cholesteryl linoleate had been incorporated was used. The test sample and the comparative sample were intravenously administered into the tail vein and 60 minutes after, the right upper arm and the right axilla lymph nodes in which tumor metastasis was noted were ectomized. Further as a non-metastatic lymph node, the left upper arm and the left axilla lymph nodes were simultaneously ectomized. Each radioactivity was measured.

40 45 As shown in Table 6, the drug carrier of the present Invention was transferred to the tumor region in a concentration as high as twice or more. In the comparative sample, such a selective delivery in a high concentration was not noted.

50 **Table 6 Delivery to Metastatic Lymph Node Tumor**

	<u>Test Sample</u>	<u>Comparative Sample</u>
Metastatic lymph nodes	2.60 \pm 0.87	0.91 \pm 0.27
Non-metastatic lymph nodes	1.04 \pm 0.27	0.86 \pm 0.39

55 Indication is (% of dose/g, mean \pm standard deviation)

Test Example 2-7a.

A test confirming a transfer to tumor region was conducted.

5 S-180 tumor cells (1×10^6) were inoculated subcutaneously to the abdominal skin of ddY strain mice (body weight: ca. 25 g). After 6 days, diameter of the tumor became about 1 cm and it was subjected to a test.

10 As to a sample, the pharmaceutical carrier of the present invention in Example 8 prepared from ^3H -labelled cholestryl linoleate was used. As a control, ^3H -labelled cholestryl linoleate was made incorporated into fat emulsion comprising yolk lecithin and soybean oil of 0.2 micron diameter and the product was used.

15 Both sample and control were administered into tail vein, then tumor was taken out after 15 minutes, 1 hour and 24 hours, and the radioactivity was determined.

16 As shown in Table 6a, the carrier of the present invention was transferred, in each time tested, to the tumor region at the concentration of about three times as much as compared with the control.

Table 6a. Transfer to Solid Tumor

Time	Tested Sample	Control
20 0.25 hr	1.37 ± 0.34	0.35 ± 0.14
1	1.64 ± 0.21	0.54 ± 0.13
24	6.59 ± 0.38	2.96 ± 1.22

25 The figures are in % of dose/g; average ± standard deviation.

Test Example 2-8

30 For purposes of confirming stability of the drug carrier of the present invention in the body in which cholestryl linoleate was the core, the drug carrier of the present invention obtained in Example 5 was used as a test sample and as a comparative sample, the drug carrier of the present invention obtained in Example 4 was used. These samples were intravenously administered to rats, respectively. Change in blood 35 concentration was determined. Samples prepared using ^3H -labeled Dexamethasone palmitate were used as the respective samples.

40 Change in total radioactivity in plasma when the test sample and the comparative sample were intravenously administered to SD male rats (weighing about 250 g) in tail vein in a dose of 0.05 mg/kg when calculated as Dexamethasone is shown in Fig. 4, by converting into Dexamethasone. The test sample disappeared from plasma more gently than the comparative sample. Half lives for the disappearance in the distribution phase were 21.6 minutes and 11.5 minutes, respectively.

Test Example 2-9

45 The test samples obtained in Examples 3, 4 and 5 and the comparative sample used in Test Example 2-1 were mixed with rat plasma, respectively to examine the stability. A concentration of the sample in plasma was made 23 $\mu\text{g}/\text{ml}$ when calculated as Dexamethasone. As shown in Table 7, the amount of the unchanged drug (Dexamethasone palmitate) remained after incubation at 37°C for 90 minutes, namely, 50 stability in plasma, was obviously superior in the drug carrier of the present invention to the comparative sample.

In addition, it was also confirmed that the use of cholestryl linoleate the core of the drug carrier of the present invention increased the stability depending upon its content.

65

Table 7 Stability in Plasma

	<u>Remaining amount of Unchanged Drug</u>
5 Test Sample obtained in Example 3	39.8%
Test Sample obtained in Example 4	47.5%
Test Sample obtained in Example 5	68.1%
10 Comparative Sample of Test Example 2-1	20.1%

15 Test Example 2-10

After applying an eye drop of test preparation to the eye of ddY mice (weighing about 30 g) under anesthesia with pentobarbital, a drug concentration in the eyeball was measured and deliverability of the drug into the eyeball was examined.

20 Test preparations are four below.

Test sample - (1) drug carrier of the present invention
 25 containing antiinflammatory guaiazulene
 obtained in Example 1

Test sample - (2) drug carrier of the present invention
 30 containing antiinflammatory guaiazulene
 obtained in Example 2

35 Comparative
 sample - (1) fat emulsion having a diameter of 0.2 μm.
 composed of soybean oil and yolk
 40 lecithin as the prior art in which
 guaiazulene had been incorporated

45 Comparative
 sample - (2) Fat emulsion having a diameter of 0.2 μm
 composed of soybean oil and yolk
 50 lecithin as the prior art in which
 sodium guaiazulene-3-sulfonate as a water
 soluble derivative of guaiazulene had
 55 been mixed and dissolved.

A dose was made 5 μg/eye when calculated as guaiazulene. After applying to the eye, the eyeball was

ectomized in a definite time. After immediately washing with physiological saline, the eyeball was homogenized and the drug was determined by high performance liquid chromatography.

Change in drug concentration in the eyeball is shown in Fig. 5. The test samples all showed better deliverability to the eyeball than the comparative samples. It is evident that delivery of the drug into the eyeball was improved in the case of using the drug carriers of the present invention.

Test Example 2-11

- 10 Using the drug carrier containing guaiazulene obtained in Example 1 as a test sample and water soluble derivative of guaiazulene sodium guaiazulene-3-sulfonate as a comparative sample, these samples were applied to the eye of Japanese white rabbits (weighing about 3 kg) to examine delivery of the drug to the aqueous humor. Thirty minutes after the eyedropping, the aqueous humor was collected and a drug concentration was measured. The results are shown in Table 8. Only in the case of using the drug carrier of 15 the present invention, delivery of the drug to the aqueous humor was noted.

**Table 8 Delivery of Drug to Aqueous Humor
after Application to the Eye**

20

Test Sample	3.47 ± 3.31
Comparative Sample	not detectable
Indication is (mean \pm standard deviation)	

30

Test Example 2-12

- Using the drug carrier of the present invention containing antihistaminic Diphenhydramine obtained in 35 Example 6 as a test sample and a Diphenhydramine hydrochloride solution in physiological saline as a comparative sample, a preventive action against accentuation of vasopermeability induced by intracutaneous administration of histamine was examined.

The test sample or the comparative sample were intravenously administered to SD strain male rats (weighing about 300 g). After a definite time period, 10 mg of Evans Blue was intravenously administered and at the same time, histamine hydrochloride ($1 \mu\text{g}/50 \mu\text{l}$) was intracutaneously injected to the abdominal skin. Further 30 minutes after, the skin was peeled apart to quantitatively determine Evans Blue exudated into the skin. After the skin was solubilized with 3 ml of conc. hydrochloric acid, 3 ml of 10% benzalconium chloride was added to the solution, Evans Blue was extracted with 5 ml of chloroform. An amount of Evans Blue exudated into the skin was determined by absorbance at 620 nm in the chloroform layer.

Fig. 8 shows time-dependent change of the inhibition of the vasopermeability induced by intracutaneously injecting histamine 15, 30 and 120 minutes after administration of both samples, doses of which were made 2 mg/kg when calculated as Diphenhydramine. The test sample showed the maximum effect already 15 minutes after the administration. The effect was continued up to 2 hours. On the other hand, in the comparative sample, its inhibition rate was lower than the test sample. The comparative sample showed the maximum effect 30 minutes after the administration and the effect was then decreased. The 50 test sample showed the inhibition of the vasopermeability by 3 times or more than the comparative sample 2 hours after the administration. By the results, it is shown that the test sample not only enhances the drug effects but also has an effect of duration in the drug action.

Fig. 7 shows a dose-response curve showing the inhibition of vasopermeability obtained 30 minutes after administration of the samples. It is evident that the test sample are excellent in the inhibition of the vasopermeability as compared to the comparative sample.

4. Brief Description of the Drawings

Fig. 1 shows results of a particle diameter of the drug carrier of the present invention prepared in Example 8 measured with a light scattering particle diameter measurement device, wherein the vertical axis represents the number of particles and the abscissa represents a particle diameter with a logarithmic scale.

Fig. 2 shows change of the total radioactivity in plasma when the test sample and the comparative sample examined in Test Example 2-1 were intravenously administered to rats, wherein the vertical axis represents a concentration of the drug calculated as Dexamethasone (ng/ml) and the abscissa represents a time passage (hour) after administration: a curve connected with ● and a curve connected with ○ represent the test sample and the comparative sample, respectively.

Fig. 3 is a dose-response curve of antiinflammatory activity obtained using a carrageenin edema inhibition rate as the index, when the test sample and the comparative sample examined in Test Example 2-2 were intravenously administered to rats, wherein the vertical axis represents a inhibitory rate of carrageenin edema by % and the abscissa represents a dose of the drug calculated as Dexamethasone with a logarithmic scale: a curve connected with ●, a curve connected with Δ and a curve connected with ○ represent the test sample, Dexamethasone phosphate and the comparative sample, respectively.

Fig. 4 represents change of the total radioactivity in plasma when the test sample and the comparative sample examined in Test Example 2-8 were intravenously administered to rats, wherein the vertical axis represents a concentration (ng/ml) of Dexamethasone calculated from the radioactivity and the abscissa represents passage of time (hour) after administration: a curve connected with ▲ and a curve connected with ● represent the test sample and the comparative sample, respectively.

Fig. 5 represents amount of the drug delivered to the eyeball after applying the two test samples and the two comparative samples examined in Test Example 2-10, wherein the vertical axis represents a concentration (ng/ml, calculated as guaiaculene) of the drug in the eyeball and the abscissa represents passage of time (hour) after application to the eye: a curve connected with ▲, a curve connected with Δ, a curve connected with ■ and a curve connected with ○ represent Test Sample - (1), Test Sample - (2), Comparative Sample - (1) and Comparative Sample - (2), respectively.

Fig. 6 represents the time courses of the inhibition of the vasopermeability when the test sample and the comparative sample examined in Test Example 2-12 were intravenously administered to rats, wherein the vertical axis represents the inhibition of the vasopermeability by per cent and the abscissa represents passage of time (hour) after administration of sample.

A curve connected with ● and a curve connected with ○ represent the test sample and the comparative sample, respectively.

Fig. 7 represents a dose-response curve in the inhibition of the vasopermeability when the test sample and the comparative sample examined in Test Example 2-12 were intravenously administered to rats, wherein the vertical axis represents the inhibition of the vasopermeability by per cent and the abscissa represents dose of the drug calculated as Diphenhydramine hydrochloride with a logarithmic scale.

A curve connected with ● and a curve connected with ○ represent the test sample and the comparative sample, respectively.

40 Claims

(1) A drug carrier in the form of a fat emulsion, which contains a drug and has a mean particle diameter of less than 200 nm.

(2) A drug carrier as claimed in claim 1 in the form of a fatty emulsion comprising a substance as the core and a surface layer, characterized in that:

① said substance constituting the core of a fat emulsion is a simple lipid, a derived lipid, a drug itself or a mixture thereof and a ratio of said substance in the drug carrier is 30 to 85%,

② said substance constituting the surface layer of a fat emulsion is a complex lipid, a derived lipid, a drug itself or a mixture thereof and a ratio of said substance in the drug carrier is 15 to 70%,
and having properties ① and ② simultaneously.

(3) A drug carrier as claimed in claim 2, wherein said simple lipid is a neutral lipid, a sterol ester or a mixture thereof.

(4) A drug carrier as claimed in claim 2, wherein said complex lipid is phospholipid, glycolipid or a mixture thereof.

(5) A drug carrier as claimed in claim 2, wherein said derived lipid is a fatty acid, a higher alcohol, a hydrocarbon or a mixture of at least two of them.

(6) A drug carrier as claimed in claim 2, wherein a mode of containing said drug is dispersing or dissolving in the drug carrier, forming a mixed micelle with a constituent(s) of the drug carrier or chemically binding with a constituent(s) of the drug carrier.

(7) A fat emulsion characterized by containing no particles having a diameter of not less than 200 nm.

5

10

15

20

25

30

35

40

45

50

55

EP 0 315 079 A1

FIG. 1






FIG. 2



F I G . 3



F I G . 4




FIG. 5




FIG. 6





FIG. 7





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 11 8025

DOCUMENTS CONSIDERED TO BE RELEVANT												
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)									
D, X	EP-A-0 211 258 (ABBOTT LABORATORIES) * Page 6, line 1 - page 7, line 31; claims * & JP-A-62 29 511 ---	1-7	A 61 K 9/10 A 61 K 9/50									
D, X	WO-A-8 701 035 (CALIFORNIA BIOTECHNOLOGY INC.) * Page 7, lines 13-17; page 14, line 11 - page 17, line 5; example 2; claims * & JP-A-63 500 456 ---	1-7										
X	EP-A-0 167 825 (Dr. RENTSCHLER ARZNEIMITTEL GmbH & CO.) * Pages 6-13; claims * ---	1-7										
X	DE-A-3 225 706 (A. NATTERMANN & CIE GmbH) * Claims; page 9, line 12; example 5 *	1-7										
P, A	EP-A-0 274 961 (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) * Claims * -----	1,2	TECHNICAL FIELDS SEARCHED (Int. Cl.4)									
			A 61 K									
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search THE HAGUE</td> <td>Date of completion of the search 15-02-1989</td> <td>Examiner BERTE M.J.</td> </tr> <tr> <td colspan="3"> CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> </tr> <tr> <td colspan="3"> <ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				Place of search THE HAGUE	Date of completion of the search 15-02-1989	Examiner BERTE M.J.	CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document 			<ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document 		
Place of search THE HAGUE	Date of completion of the search 15-02-1989	Examiner BERTE M.J.										
CATEGORY OF CITED DOCUMENTS <ul style="list-style-type: none"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document 												
<ul style="list-style-type: none"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document 												



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 31 0278

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	WO-A-8 203 769 (GEORGETOWN UNIVERSITY) ---		A 61 K 9/50
D,A	US-A-4 663 167 (G. LOPEZ-BERESTEIN et al.) * Column 5, lines 1-40 * ---		A 61 K 31/71
P,A	EP-A-0 272 091 (VESTAR, INC.) * Page 3, line 40 - page 4, line 14; page 14, lines 1-9; claims 1-18 * -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			A 61 K
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	17-02-1989	BENZ K. F.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EP FORM 1501 (02-82) (P001)